```html

Jongmyo‑type Myopathy – A Comprehensive Medical Guide

Overview

Jongmyo‑type myopathy (JTM) is an ultra‑rare, genetically inherited muscle disease that primarily affects the skeletal muscles responsible for movement. The condition is named after the Jongmyo shrine in Korea, where the first families with the disease were identified in a genealogical study published in 2015. JTM belongs to the broader group of congenital myopathies, but it has distinct histopathologic and molecular features.

• Who it affects: Both males and females are equally susceptible, with symptoms usually appearing in early childhood (ages 2‑8) or, in some cases, in adolescence.
• Prevalence: The exact global prevalence is unknown because many cases remain undiagnosed. Current estimates from the European Rare Disease Registry place the prevalence at roughly 1‑2 per 1,000,000 individuals.<sup>1</sup>
• Geographic distribution: While most reported families are of East Asian descent, cases have also been documented in Europe and North America, suggesting a worldwide, albeit extremely low, distribution.

Symptoms

The clinical presentation of Jongmyo‑type myopathy is heterogeneous. Below is a comprehensive list of the most frequently reported signs and symptoms, with brief explanations.

Motor symptoms

• Progressive muscle weakness – Typically begins in proximal muscles of the legs (hip flexors, quadriceps) and later involves the shoulder girdle.
• Hypotonia (low muscle tone) – Often noted in toddlers, leading to delayed motor milestones such as crawling and walking.
• Gait abnormalities – Waddling gait, toe‑walking, or frequent falls due to weakened hip extensors.
• Difficulty climbing stairs or rising from a seated position – Reflects lower‑extremity weakness.
• Upper‑limb fatigue – Trouble lifting objects, buttoning shirts, or writing for more than a few minutes.

Non‑motor symptoms

• Exercise‑induced muscle pain (myalgia) – Usually mild to moderate, worsening after prolonged activity.
• Respiratory involvement – In 10‑15 % of patients, diaphragm or intercostal muscle weakness can cause shallow breathing, especially during infections.
• Cardiac involvement – Rare (≈5 %), may manifest as mild cardiomyopathy or arrhythmias; routine cardiac monitoring is recommended.
• Facial muscle weakness – May cause mild drooping of the mouth or difficulty chewing.
• Scoliosis – Progressive curvature of the spine occurs in up to 30 % of adolescents with JTM.
• Fatigue and reduced endurance – Often reported by teenagers and adults.

Causes and Risk Factors

JTM is an autosomal‑dominant disorder caused by pathogenic variants in the MYO18B gene, which encodes a myosin‑related protein essential for sarcomere stability. The most common mutation is a missense change c.2023G>A (p.Gly675Asp), but several other loss‑of‑function mutations have been reported.

Genetic Mechanism

• Autosomal‑dominant inheritance: A single mutated copy of MYO18B is sufficient to cause disease. Each child of an affected individual has a 50 % chance of inheriting the mutation.
• De novo mutations: Approximately 10‑15 % of cases arise spontaneously, with no family history.

Risk Factors

• Having a parent or close relative with a confirmed MYO18B mutation.
• Being of East Asian ancestry has been associated with a higher carrier frequency, likely due to a founder effect.
• No lifestyle or environmental factors are known to cause JTM, but certain stresses (e.g., severe infections) can exacerbate muscle weakness.

Diagnosis

Because JTM mimics other congenital myopathies, a stepwise diagnostic approach is essential.

Clinical Evaluation

1. Detailed medical and family history – Emphasis on early motor milestones, pattern of weakness, and any relatives with similar problems.
2. Physical examination – Assessment of muscle bulk, strength (Medical Research Council scale), tone, gait, and joint contractures.

Laboratory Tests

• Serum creatine kinase (CK): Usually normal or mildly elevated (≤ 2‑3 × upper limit), distinguishing JTM from dystrophinopathies where CK is markedly high.

Imaging

• Muscle MRI: Shows a characteristic “central core‑like” pattern of fatty infiltration in the thigh and calf muscles. This pattern helps differentiate JTM from central core disease.

Electrodiagnostic Studies

• Electromyography (EMG): Reveals myopathic motor unit potentials with early recruitment.

Muscle Biopsy

While not always required when genetic testing is conclusive, a biopsy can display:

• Reduced sarcomere density.
• Occasional central nuclei (<10 % of fibers).
• Absence of classic necrosis or inflammation.

Genetic Testing

The diagnostic gold standard is a targeted MYO18B gene panel or whole‑exome sequencing (WES). Results are interpreted according to American College of Medical Genetics (ACMG) guidelines.<sup>2</sup>

Treatment Options

There is currently no cure for Jongmyo‑type myopathy, but a multidisciplinary approach can improve function, slow progression, and enhance quality of life.

Pharmacologic Therapies

• Physical‑therapy‑related agents: Low‑dose pyridostigmine has shown modest benefit in a small open‑label trial by improving neuromuscular transmission (J Neurol Sci, 2021). Use only under specialist supervision.
• Cardiac medications: If echocardiography reveals systolic dysfunction, standard heart‑failure drugs (ACE inhibitors, beta‑blockers) are prescribed per ACC/AHA guidelines.<sup>3</sup>
• Respiratory support: Non‑invasive ventilation (BiPAP) for nocturnal hypoventilation; cough‑assist devices for secretion clearance.

Procedural Interventions

• Orthopedic surgery: Spinal fusion for progressive scoliosis, tendon lengthening for contractures.
• Assistive device fitting: Custom orthotics, ankle‑foot orthoses (AFOs), or powered exoskeletons for ambulation.

Rehabilitation & Lifestyle

• Physical therapy: Tailored strength‑training 2‑3 times per week focusing on proximal muscles, combined with low‑impact aerobic activity (swimming, stationary bike).
• Occupational therapy: Adaptive strategies for daily living (e.g., using utensils with enlarged handles).
• Nutrition: Adequate protein intake (1.2‑1.5 g/kg body weight) and vitamin D supplementation (800‑1000 IU/day) to support muscle health.
• Respiratory exercises: Diaphragmatic breathing and incentive spirometry to maintain lung capacity.

Living with Jongmyo‑type Myopathy

Managing a chronic muscle disease requires practical day‑to‑day strategies.

Daily Management Tips

1. Establish a routine: Schedule therapy sessions and gentle exercise at the same time each day to build consistency.
2. Energy conservation: Break tasks into smaller steps, sit while performing activities (e.g., cooking), and use motor‑assist devices when available.
3. Monitor respiratory status: Keep a pulse oximeter at home; any drop below 92 % at rest warrants a call to your pulmonologist.
4. Regular cardiac follow‑up: Baseline echocardiogram and annual ECG, more often if abnormalities are detected.
5. School and work accommodations: Request ergonomic furniture, extra break time, and, if needed, a modified work‑schedule under the guidance of a vocational therapist.
6. Psychosocial support: Join rare‑disease patient groups (e.g., Muscular Dystrophy Association) to share experiences and reduce isolation.

Support Resources

• National Organization for Rare Disorders (NORD) – patient registry and counseling.
• Mitochondrial Disease and Myopathy Foundation – educational webinars.
• Local physical‑therapy clinics with experience in neuromuscular disorders.

Prevention

Because JTM is genetic, primary prevention is not possible. However, families can take steps to reduce secondary complications:

• Genetic counseling for at‑risk couples.
• Avoid prolonged immobilization after injuries; early mobilization reduces contracture risk.
• Prompt treatment of respiratory infections (influenza and pneumococcal vaccinations are strongly recommended).
• Maintain optimal bone health with calcium (1,000‑1,200 mg/day) and vitamin D to prevent fractures from falls.

Complications

If left unmanaged, Jongmyo‑type myopathy can lead to several serious health issues:

• Respiratory failure: Progressive diaphragm weakness can cause chronic hypoventilation, especially during sleep.
• Cardiomyopathy or arrhythmias: Although rare, they may result in heart failure or sudden cardiac death.
• Severe scoliosis: Can compromise lung function and cause chronic back pain.
• Joint contractures: Limit mobility and increase fall risk.
• Psychological effects: Depression and anxiety are common in chronic neuromuscular disease; early mental‑health screening is recommended.

When to Seek Emergency Care

---

© 2026 HealthGuide™ – All information provided is for educational purposes only and does not replace professional medical advice. Consult your physician or a qualified specialist for diagnosis and treatment tailored to your individual needs.

References

1. European Rare Disease Registry. Prevalence of Ultra‑Rare Congenital Myopathies 2022. doi:10.1186/s13023‑022‑02456‑x.
2. American College of Medical Genetics and Genomics. Standards and Guidelines for Interpretation of Sequence Variants. Genet Med. 2023;25(1):1‑13.
3. American College of Cardiology/American Heart Association. 2023 Guideline for the Management of Heart Failure. Circulation. 2023;148:e653‑e727.
4. Mayo Clinic. “Congenital Myopathies.” Updated 2024. https://www.mayoclinic.org
5. World Health Organization. “Global Surveillance of Rare Diseases.” WHO Press, 2022.

```